title: [Comparative study on the effect of highly active antiretroviral therapy (HAART) in patients with HIV infection acquired by blood transfusion and paid plasma donation].
abstract: OBJECTIVE
  To study the effect of HAART in patients with AIDS acquire by blood transfusion and paid plasma donation.
  
  
  METHODS
  All AIDS patients whose disease was caused by blood transfusion and commercial plasma donation came from the domicile of Hebei Province. In the group of cases of blood transfusion in whom the infection was caused by one-time blood transfusion before and after 1995, there were 189 cases, of whom 105 cases on HAART were designated as observation group, and 84 cases who were not on HAART were designated as control group. The group of AIDS patients who were former commercial plasma donors (FCPDs) had 120 patients who were identified in the survey of 1995, of whom 63 cases on HAART were designated as observation group and 57 cases who were not on HAART were as control group. Onset dates were defined as the dates into the queue. Death due to AIDS was regarded as an outcome event. Subjects who were enrolled into the observation group and control group were epidemiologically followed up regularly. Observation was ended on December 31, 2010.
  
  
  RESULTS
  Mortality of patients after HAART from groups of FCPDs and blood recipients were 4.42/100 person-years and 6.13/100 person-years, respectively. The survival rates of HAART groups were 80% in FCPDs for 110 months and 72% in blood recipients for 90 months, respectively. Meanwhile the mortality of no HAART groups were 182.05/100 person-years and 250.66/100 person-years, respectively. Mean survival of patients whose disease was caused by plasma donation and blood transfusion were 4 months and 3 months, respectively.
  
  
  CONCLUSIONS
  Whether the HIV infection was caused by plasmapheresis or blood transfusion, the effects of HAART did not show difference. HAART cold reduce the death intensity and prolong survival.
authors.affiliation: Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China. chensuliang@sina.com
authors.forename: Su-Liang
authors.initials: SL
authors.lastname: Chen
authors.forename: Yu-Qi
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Hong-Ru
authors.initials: HR
authors.lastname: Zhao
authors.forename: Zhi-Qiang
authors.initials: ZQ
authors.lastname: Chen
authors.forename: Bao-Jun
authors.initials: BJ
authors.lastname: Li
authors.forename: Cui-Ying
authors.initials: CY
authors.lastname: Zhao
authors.forename: Guang-Yi
authors.initials: GY
authors.lastname: Bai
authors.forename: Liang
authors.initials: L
authors.lastname: Liang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000635:transmission*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001782:Blood Donors; D005260:Female; D006801:Humans; D008297:Male; D015996:Survival Rate; D065227:Transfusion Reaction